Holen Sie sich die Stockscreener-App
3.675
11.70%
0.385
Vorhandelsmarkt:
3.74
0.065
+1.77%
Schlusskurs vom Vortag:
$3.29
Offen:
$3.3
24-Stunden-Volumen:
9.87M
Relative Volume:
1.86
Marktkapitalisierung:
$552.62M
Einnahmen:
$4.21M
Nettoeinkommen (Verlust:
$-97.67M
KGV:
-3.9516
EPS:
-0.93
Netto-Cashflow:
$-70.76M
1W Leistung:
+18.93%
1M Leistung:
-6.73%
6M Leistung:
+28.95%
1J Leistung:
+18.93%
1-Tages-Spanne:
$3.29
$3.96
1-Wochen-Bereich:
$2.985
$3.96
52-Wochen-Spanne:
$2.01
$6.33
Absci Corp Stock (ABSI) Company Profile
Firmenname
Absci Corp
Sektor
Branche
Telefon
(360) 949-1041
Adresse
18105 SE MILL PLAIN BLVD, VANCOUVER
Vergleichen Sie ABSI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
3.675 | 494.72M | 4.21M | -97.67M | -70.76M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-02 | Eingeleitet | JP Morgan | Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-01-22 | Eingeleitet | Needham | Buy |
| 2024-10-02 | Eingeleitet | Guggenheim | Buy |
| 2024-07-03 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-03-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2023-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-07-18 | Eingeleitet | Truist | Buy |
| 2022-03-02 | Fortgesetzt | Cowen | Market Perform |
| 2022-02-01 | Eingeleitet | Berenberg | Buy |
| 2021-11-10 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-08-16 | Eingeleitet | BofA Securities | Neutral |
| 2021-08-16 | Eingeleitet | Cowen | Market Perform |
| 2021-08-16 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-16 | Eingeleitet | Stifel | Hold |
Alle ansehen
Absci Corp Aktie (ABSI) Neueste Nachrichten
Assessing Absci (ABSI) Valuation After First Volunteers Dosed in ABS-201 HeadLINE Trial - simplywall.st
Absci Corp. Strives for New Horizons Amid Financial Adjustments - timothysykes.com
Absci announces first participants dosed in Phase 1/2a HEADLINE trial - TipRanks
Absci (ABSI): Assessing Valuation as AI‑Designed Hair Loss Drug Enters First Phase 1/2a Trial - Yahoo Finance
Absci doses first volunteers in phase 1/2a trial of hair loss antibody - Investing.com Australia
Absci Announces First Participants Dosed In Phase 1/2A Headline Trial - TradingView
Absci (Nasdaq: ABSI) doses first volunteers in Phase 1/2a ABS-201 hair loss trial - Stock Titan
Will Absci Corporation stock deliver shareholder valueJuly 2025 Opening Moves & AI Optimized Trade Strategies - Newser
Absci stock price target raised to $9 from $8 at Jones Trading By Investing.com - Investing.com South Africa
Absci stock price target raised to $9 from $8 at Jones Trading - Investing.com Canada
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating - 富途牛牛
Absci Corp. Experiences Revision in Its Stock Evaluation Amid Mixed Financial Performance - Markets Mojo
Will Absci Corporation see short term momentumWeekly Trade Analysis & Risk Controlled Daily Trade Plans - newser.com
How Absci Corporation stock benefits from tech adoptionJuly 2025 Sector Moves & Low Risk High Win Rate Stock Picks - newser.com
Can trapped investors hope for a rebound in Absci CorporationGlobal Markets & Community Shared Stock Ideas - newser.com
Can Absci Corporation stock double in next 5 yearsMarket Growth Report & Expert Approved Momentum Trade Ideas - newser.com
Will Absci Corporation stock maintain growth storyJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - newser.com
Absci Corp’s Earnings Call Highlights Strategic Growth - MSN
Can Absci Corporation stock deliver sustainable ROE2025 Price Action Summary & Momentum Based Trading Ideas - newser.com
Absci (ABSI) Valuation in Focus as Clinical Expansion and Partnership Efforts Gather Pace - Yahoo Finance
Can Absci Corporation stock surprise with earnings upsideJuly 2025 Closing Moves & AI Powered Buy/Sell Recommendations - newser.com
Real time pattern detection on Absci Corporation stockPortfolio Update Summary & Proven Capital Preservation Methods - newser.com
Absci Corporation Advances AI-Driven Therapeutics - MSN
Absci Corporation (NASDAQ:ABSI) Q3 2025 Earnings Call Transcript - Insider Monkey
Absci Stock Takes a Leap: What’s Next? - StocksToTrade
Needham & Company LLC Cuts Absci (NASDAQ:ABSI) Price Target to $7.00 - MarketBeat
Why Absci Corporation stock remains a top recommendation2025 Key Lessons & Long-Term Growth Portfolio Plans - Fundação Cultural do Pará
Is Absci’s (ABSI) Lower Per-Share Loss a Sign of Rising Efficiency or Just a Temporary Shift? - Yahoo Finance
Absci (NASDAQ:ABSI) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Is Absci Corporation stock dividend yield sustainableDollar Strength & Short-Term Trading Alerts - newser.com
H.C. Wainwright Maintains Absci Corp(ABSI.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Absci reports Q3 EPS (20c), consensus (21c) - MSN
Absci expects cash to fund operations into the first half of 2028 - MSN
AbSci Corp options imply 13.2% move in share price post-earnings - MSN
Absci (ABSI) Q3 2025 Earnings Call Transcript - Nasdaq
Ardent Health, KinderCare Learning, Ibotta And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market SessionAbsci (NASDAQ:ABSI), Ardent Health (NYSE:ARDT) - Benzinga
Needham Maintains Buy Rating for ABSI, Lowers Price Target | ABS - GuruFocus
Needham Maintains Absci Corp(ABSI.US) With Buy Rating, Cuts Target Price to $7 - 富途牛牛
Absci Corporation (ABSI) Reports Q3 Loss, Lags Revenue Estimates - sharewise.com
Finanzdaten der Absci Corp-Aktie (ABSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):